

Revised Draft Agenda
Biocides Working Group Meeting V-2017

14 - 24 November 2017

ECHA Conference Centre (Annankatu 18, Helsinki)

Meeting room Margot Wallstrom (MW)

Meeting room Guido Sacconi (GS)

Meeting room Marie Curie (MC)

Coffee break 11:00-11:30

Lunch break 13:00-14:00

Coffee break 15:30-16:00

Tuesday 14 Nov	09:00-13:00	APCP WG (GS)
	14:00-18:00	
Wednesday 15 Nov	09:00-13:00	APCP WG (GS)
	14:00-17:00	
Wednesday 15 Nov	09:30-13:00	EFF WG (MC)
	14:00-18:00	
Thursday 16 Nov	09:00-13:00	EFF WG (MC)
	14:00-16:00	
Tuesday 21 Nov	09:30-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 22 Nov	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Thursday 23 Nov	09:00-13:00	TOX WG (MW)
	14:00-17:00	
Wednesday 22 Nov	09:00-13:00	ENV WG (GS)
	14:00-18:00	
Thursday 23 Nov	09:00-13:00	ENV WG (MC)
	14:00-18:00	
Friday 24 Nov	09:00-13:00	ENV WG (MC)

Analytical methods and physico-chemical properties Working Group

Chair: Bernhard Krebs

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-IV-2017

Meeting documents:

WG IV 2017_APCP_6-1_draft minutes

WG IV 2017_APCP_7-2_draft minutes

WG IV 2017_APCP_7-3_draft minutes

WG IV 2017_APCP_7-4_draft minutes

WG IV 2017_APCP_7-5_draft minutes

WG IV 2017_APCP_7-6_draft minutes

WG IV 2017_APCP_8-1_draft minutes

WG IV 2017_APCP_8-2_draft minutes

WG IV 2017_APCP_8-3_draft minutes

WG IV 2017_APCP_8-4_draft minutes

WG IV 2017_APCP_9-2-1_draft minutes

WG IV 2017_APCP_9-2-2_draft minutes

WG IV 2017_APCP_gen_agenda_items_draft minutes

For agreement

Item 6 – Follow-up of previous working group meetings and e-consultations

6.1 Follow-up of previous working group meetings

For discussion/information

Item 7 – Technical and scientific issues and early working group discussions

- 7.1 CHED - naming and requirements on physico-chemical tests - early working group discussion (eCA NO)**
Meeting documents: WG V 2017_APCP_7-1
For discussion/agreement
- 7.2 Definition of 'in situ' on the example of chlorine dioxide (eCA DE)**
Meeting documents: WG V 2017_APCP_7-2
For discussion/agreement
- 7.3 Residue of distillation of peracetic acid**
Meeting document: WG V 2017_APCP_7-3
For discussion/agreement

Item 8 – Discussion of active substances

- 8.1 Salicylic acid (eCA NL)**
PT 02, 03, 04
Meeting documents: WG V 2017_APCP_8-1
For discussion/agreement
- 8.2 DDAC (eCA IT)**
PT 03, 04
Meeting documents: WG V 2017_APCP_8-2
For discussion/agreement
- 8.3 ADBAC (eCA IT)**
PT 03, 04
Meeting documents: WG V 2017_APCP_8-3
For discussion/agreement
- 8.4 Chlorfenapyr (eCA PT)**
PT 18
Meeting documents: WG V 2017_APCP_8-4
For discussion/agreement
- 8.5 Silver zeolite (eCA SE)**
PT 02, 04, 07, 09
Meeting documents: WG V 2017_APCP_8-5
For discussion/agreement
- 8.6 Silver copper zeolite (eCA SE)**
PT 02, 04, 07, 09
Meeting documents: WG V 2017_APCP_8-6
For discussion/agreement
- 8.7 Silver sodium hydrogen zirconium phosphate (eCA SE)**
PT 02, 04, 07, 09
Meeting documents: WG V 2017_APCP_8-7
For discussion/agreement

Item 9 – AOB

Efficacy Working Group
Chair: Katarzyna Szymankiewicz

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-IV-2017

Meeting documents:

- *WGIV2017_EFF_6-1_draft_minutes.docx*
- *WGIV2017_EFF_6-2_draft_minutes.docx*
- *WGIV2017_EFF_6-3_draft_minutes.docx*
- *WGIV2017_EFF_6-4_draft_minutes.docx*
- *WGIV2017_EFF_6-5_draft_minutes.docx*
- *WGIV2017_EFF_6-6_draft_minutes.docx*
- *WGIV2017_EFF_draft_minutes.docx*

For agreement

Item 6 – Discussion of active substances

6.1 ADBAC (eCA IT)

PT 03, 04

Meeting document: *WGV2017_EFF_6-1*

For discussion/agreement

6.2 DDAC (eCA IT)

PT 03, 04

Meeting document: *WGV2017_EFF_6-2*

For discussion/agreement

6.3 Salicylic acid (eCA NL)

PT 02, 03, 04

Meeting document: *WGV2017_EFF_6-3*

For discussion/agreement

6.4 Chlorfenapyr (eCA PT)

PT 18

Meeting document: *WGV2017_EFF_6-4*

For discussion/agreement

- 6.5 Silver sodium hydrogen zirconium phosphate (eCA SE)**
PT 02, 04, 07, 09
Meeting document: *WGV2017_EFF_6-5*
For discussion/agreement
- 6.6 Silver copper zeolite (eCA SE)**
PT 02, 04, 07, 09
Meeting document: *WGV2017_EFF_6-6*
For discussion/agreement
- 6.7 Silver zeolite (eCA SE)**
PT 02, 04, 07, 09
Meeting document: *WGV2017_EFF_6-7*
For discussion/agreement
- 6.8 Sulphur dioxide generated from sulphur by combustion - early WG discussion (eCA DE)**
PT 04
Meeting document: *WGV2017_EFF_6-8*
For discussion/agreement
- 6.9 Sodium metabisulphite releasing sulphur dioxide - early WG discussion (eCA DE)**
PT09
Meeting document: *WGV2017_EFF_6-9*
For discussion/agreement

Item 7 – Technical and guidance related issues

- 7.1 Update on guidance development (ECHA)**
For information
- 7.2 PT18 - Clarification on tests needed for a general claim against 'Other arthropods' (ECHA)**
Meeting document: *WGV2017_EFF_7-2*
For discussion
- 7.3 Information on virucidal claims – recommendation for the EFF WG website (AT) – closed session**
Meeting document: *WGV2017_EFF_7-3*
For discussion

Item 8 – AOB

- 8.1 Efficacy testing in PT6,11 and 12: range of dosage recommendations (NL) – closed session**
Meeting document: *WGV2017_EFF_8-1*
For discussion
- 8.2 Room disinfection - how to ensure the proper use (NL) – post WGIV2017 comments**
Meeting document: *WGV2017_EFF_8-2*
For discussion

8.3 Textile disinfection (NL) – post WGIV2017 comments

Meeting document: *WGV2017_EFF_8-3*

For discussion

8.4 Update on Union Authorisation (ECHA)

SECR to inform

For information

8.5 Other information & lessons learned (ECHA)

SECR/WG members to inform and to reflect on the experience gained

For information

Human Health Working Group

Chair: Antero Airaksinen

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-IV-2017

Draft minutes:

- WGIV2017_TOX_6-1
- WGIV2017_TOX_6-2
- WGIV2017_TOX_6-3
- WGIV2017_TOX_6-4
- WGIV2017_TOX_6-5
- WGIV2017_TOX_6-6
- WGIV2017_TOX_6-7
- WGIV2017_TOX_7-2
- WGIV2017_TOX_minutes_draft.docx

For agreement

Item 6 – Discussion of active substances

6.1 ADBAC (eCA IT)

PT 03, 04

Meeting document: WGV2017_TOX_6-1

For discussion/agreement

6.2 DDAC (eCA IT)

PT 03, 04

Meeting document: WGV2017_TOX_6-2

For discussion/agreement

6.3 Salicylic acid (eCA NL)

PT 02, 03, 04

Meeting document: WGV2017_TOX_6-3

For discussion/agreement

6.4 Chlorfenapyr (eCA PT)

PT 18

Meeting document: WGV2017_TOX_6-4

For discussion/agreement

- 6.5 Silver sodium hydrogen zirconium phosphate (eCA SE)**
 PT 02, 04, 07, 09
 Meeting document: *WGV2017_TOX_6-5*
For discussion/agreement
- 6.6 Silver copper zeolite (eCA SE)**
 PT 02, 04, 07, 09
 Meeting document: *WGV2017_TOX_6-6*
For discussion/agreement
- 6.7 Silver zeolite (eCA SE)**
 PT 02, 04, 07, 09
 Meeting document: *WGV2017_TOX_6-7*
For discussion/agreement
- 6.8 Early WG discussion: Sodium metabisulphite releasing sulphur dioxide (eCA DE)**
 PT 09
 Meeting document: *WGV2017_TOX_6-8*
For discussion/agreement
- 6.9 Early WG discussion: Sulphur dioxide generated from sulphur by combustion (eCA DE)**
 PT 04
 Meeting document: *WGV2017_TOX_6-9*
For discussion/agreement

Item 7 – Technical and guidance related issues

- 7.1 Update on guidance development**
 SECR to inform
For information
- 7.2 Recommendations of HEAdhoc**
- (a) Exposure to anticoagulant rodenticides via sachets**
 Meeting document: *WGV2017_TOX_7-2a*
For agreement
- (b) Alignment of HEAdhoc Recommendation 11 to EFF WG agreement**
 Meeting document: *WGV2017_TOX_7-2b*
For agreement
- 7.3 Iodine background in milk and iodine dietary intake**
 Meeting document: *WGV2017_TOX_7-3*
For agreement
- 7.4 Toxicological relevance of metabolites in groundwater**
 Meeting document: *WGV2017_TOX_7-4*
For discussion/agreement
- 7.5 Local risk assessment – approach for substances that do not trigger classification of the product**
 Meeting document: *WGV2017_TOX_7-5*
For discussion/agreement

Item 8 – AOB

8.1 Update on Union Authorisation (ECHA)

SECR to inform

For information

8.2 Other information & lessons learned

SECR/WG members to inform and to reflect on the experience gained

For information

Environment Working Group
Chair: Heike Schimmelpfennig

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-IV-2017

Meeting documents:

- *WGIII2017_ENV_6-3_6-4_d-allethrin_esbiothrin_PT18_Updated minutes*
- *WGIV2017_ENV_6-1_Draft minutes*
 - *WGIV2017_ENV_6-2_Draft minutes*
 - *WGIV2017_ENV_6-3_Draft minutes*
 - *WGIV2017_ENV_6-4_Draft minutes*
 - *WGIV2017_ENV_6-5_Draft minutes*
 - *WGIV2017_ENV_6-6_Draft minutes*
 - *WGIV2017_ENV_General_Draft minutes*

For agreement

Item 6 – Discussion of active substances

6.1 Chlorfenapyr (eCA PT)

PT 18

Meeting document: *WGV2017_ENV_6-1*

For discussion/agreement

6.2 Salicylic acid (eCA NL)

PT 02, 03, 04

Meeting document: *WGV2017_ENV_6-2*

For discussion/agreement

6.3 ADBAC (eCA IT)

PT 03, 04

Meeting document: *WGV2017_ENV_6-3*

For discussion/agreement

6.4 DDAC (eCA IT)

PT 03, 04

Meeting document: *WGV2017_ENV_6-4*

For discussion/agreement

6.5 Silver sodium hydrogen zirconium phosphate (eCA SE)

PT 02, 04, 07, 09

Meeting document: *WGV2017_ENV_6-5*

For discussion/agreement

6.6 Silver copper zeolite (eCA SE)

PT 02, 04, 07, 09

Meeting document: *WGV2017_ENV_6-6*

For discussion/agreement

6.7 Silver zeolite (eCA SE)

PT 02, 04, 07, 09

Meeting document: *WGV2017_ENV_6-7*

For discussion/agreement

Item 7 – Technical/guidance related issues (including AHEE members)

7.1 Update on guidance development and work of the AHEE (ECHA)

Meeting document: *WGV2017_ENV_7-1*

For information

Item 8 – AOB

8.1 Other information & lessons learned

SECR/WG members to reflect on the experience gained

For information

o0o